Dabigatran Etexilate

Generic Name: dabigatran etexilate

Over-the-Counter (OTC)

Brand Names:

Dabigatran

Dabigatran etexilate mesylate is a direct thrombin inhibitor available in 75 mg, 110 mg, and 150 mg capsule strengths with inactive ingredients including croscarmellose sodium and magnesium stearate.

Overview

Dabigatran etexilate mesylate is a direct thrombin inhibitor available in 75 mg, 110 mg, and 150 mg capsule strengths with inactive ingredients including croscarmellose sodium and magnesium stearate.

Uses

Indicated for reducing stroke and systemic embolism risk in non-valvular atrial fibrillation; treating DVT and PE after parenteral anticoagulation; reducing recurrence risk of DVT/PE; and prophylaxis of DVT/PE following hip replacement surgery in adult patients.

Dosage

Dosing varies by indication and renal function. For atrial fibrillation: 150 mg twice daily (CrCl greater than 30) or 75 mg twice daily (CrCl 15-30). Capsules must be swallowed whole with water; breaking increases exposure.

Side Effects

Most common adverse reactions include gastrointestinal effects and bleeding. Major bleeding rate comparable to warfarin at 3.47% annually; higher GI bleeding at 1.59% annually versus 1.05% with warfarin.

Interactions

Avoid P-gp inducers (rifampin). Manage P-gp inhibitor use based on renal function; dose reduction or avoidance required with severe renal impairment.

Warnings

Two critical warnings: (A) premature discontinuation increases thrombotic event risk; (B) spinal/epidural hematoma risk with neuraxial anesthesia, potentially causing permanent paralysis. Contraindicated in active pathological bleeding, serious hypersensitivity reactions, and mechanical prosthetic heart valves.

Pregnancy

Limited human data. Animal studies showed increased fetal death, bleeding, and ossification delays at exposures 2.6-8 times human levels.

Frequently Asked Questions

What is Dabigatran Etexilate used for?

Indicated for reducing stroke and systemic embolism risk in non-valvular atrial fibrillation; treating DVT and PE after parenteral anticoagulation; reducing recurrence risk of DVT/PE; and prophylaxis of DVT/PE following hip replacement surgery in adult patients.

What are the side effects of Dabigatran Etexilate?

Most common adverse reactions include gastrointestinal effects and bleeding. Major bleeding rate comparable to warfarin at 3.47% annually; higher GI bleeding at 1.59% annually versus 1.05% with warfarin.

Can I take Dabigatran Etexilate during pregnancy?

Limited human data. Animal studies showed increased fetal death, bleeding, and ossification delays at exposures 2.6-8 times human levels.

What are the important warnings for Dabigatran Etexilate?

Two critical warnings: (A) premature discontinuation increases thrombotic event risk; (B) spinal/epidural hematoma risk with neuraxial anesthesia, potentially causing permanent paralysis. Contraindicated in active pathological bleeding, serious hypersensitivity reactions, and mechanical prosthetic heart valves.

Related Medications

Medical Disclaimer

This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.